Immune cells armed to fight pancreatic cancer: a new hope?
NCT ID NCT04137536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is to find the safest dose and understand possible side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University of Virginia (Specimen Analysis)
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new imaging trick spot pancreatic cancer without a biopsy?
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?